Influencing factors of postoperative survival in patient with gastric cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

XIAO Zhengjie ¹ ,  TIAN Qinggang ² , HAI Erhan ³

1. Department of General Surgery, The Fourth Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia 014040, P. R. China;
2. Department of Oncology Surgery, The Fourth Hospital of Baotou City, Baotou, Inner Mongolia 014030, P. R. China;
3. Department of General Surgery, Baotou Central Hospital, Baotou, Inner Mongolia 014040, P. R. China;

Corresponding?author：

TIAN Qinggang, Email: tianqinggang2004@163.com

Keywords：

gastric cancer; survival time; influencing factor

DOI：

10.7507/1007-9424.202009057

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the related factors of postoperative survival of patient with gastric cancer, so as to provide the corresponding evidence support for the prognosis evaluation.Methods The clinicopathologic data of patients with gastric cancer who underwent surgical treatment in the Fourth Affiliated Hospital of Baotou Medical College and the Fourth Hospital of Baotou City from January 2006 to December 2009 were retrospectively collected. The influences of clinicopathologic data (gender, age, tumor size, tumor location, lymph node metastasis, tumor thrombus, tumor differentiation, TNM stage, operation mode, and postoperative chemotherapy) on postoperative survival of patients with gastric cancer were analyzed. Univariate analysis was used to analyze the influencing factors of postoperative survival in the patients with gastric cancer and Cox proportional hazards regression was used to analyze the independent risk factors.Results A total of 80 patients with gastric cancer were included in this study. Up to December 31, 2014, the median survival time at 50% cumulative survival rate was 95 months. Univariate analysis showed that the survival of patients with gastric cancer was related to tumor size, lymph node metastasis, tumor differentiation, and TNM stage (P<0.05). Further multivariate analysis showed that later TNM stage was an independent risk factor for affecting postoperative survival of patients with gastric cancer (P<0.05).Conclusion Postoperative survival of patients with gastric cancer is related to tumor size, lymph node metastasis, tumor differentiation, and TNM stage; And later TNM stage is an independent risk factor for affecting survival of patients with gastric cancer.

Citation： XIAO Zhengjie, TIAN Qinggang, HAI Erhan. Influencing factors of postoperative survival in patient with gastric cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(7): 884-887. doi: 10.7507/1007-9424.202009057 Copy

1.	Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol, 2017, 3(4): 524-548.
2.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
3.	Eusebi LH, Telese A, Marasco G, et al. Gastric cancer prevention strategies: A global perspective. J Gastroenterol Hepatol, 2020, 35(9): 1495-1502.
4.	Machlowska J, Baj J, Sitarz M, et al. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci, 2020, 21(11): 4012.
5.	Habib R, Akhtar J, Taqi M, et al. Lentiviral vector-mediated survivin shRNA delivery in gastric cancer cell lines significantly inhibits cell proliferation and tumor growth. Oncol Rep, 2015, 34(2): 859-867.
6.	徐冉, 楊年釗, 趙海遠, 等. 多灶性胃癌病人淋巴結轉移危險因素及預后分析. 臨床外科雜志, 2020, 28(8): 774-777.
7.	許巧玲, 鄭鴻. 伊立替康聯合阿帕替尼治療晚期胃癌預后分析. 腫瘤研究與臨床, 2020, 32(6): 419-423.
8.	Zhao Z, Fan Y, Sun Y, et al. Efficacy of conversion surgery on stage Ⅳ gastric cancer and its prognosis analysis. Panminerva Med, 2020 May 14. Online ahead of print.
9.	崔勇, 張榮香, 王福立, 等. 新輔助化療聯合術后同步放化療治療Ⅲ期胃癌的療效分析. 中國腫瘤臨床, 2016, 43(17): 747-752.
10.	李敏娜, 路寧, 王藝璇, 等. 中青年與老年胃癌術后患者的臨床病理特點和預后因素—基于 SEER 數據庫的分析. 現代腫瘤醫學, 2020, 28(14): 2467-2473.
11.	李靜. miRNA-451 表達與胃癌患者預后相關性分析. 慢性病學雜志, 2020, 21(7): 974-976.
12.	馬翔. 胃癌手術治療后超長期生存患者預后因素分析. 腫瘤研究與臨床, 2019, 31(9): 630-632.
13.	蔣大平, 徐華平, 方華進, 等. 影響胃癌根治術后患者預后效果的相關因素分析. 中國現代醫學雜志, 2020, 30(4): 39-43.
14.	廖玉麟, 徐宏濤, 周煜. 營養狀況及心理因素對胃癌患者半年生存率及生存質量的影響. 中國現代醫生, 2016, 54(10): 30-33.
15.	Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin, 2017, 67(2): 93-99.
16.	Liu JY, Peng CW, Yang XJ, et al. The prognosis role of AJCC/UICC 8 th edition staging system in gastric cancer, a retrospective analysis. Am J Transl Res, 2018, 10(1): 292-303.
17.	Kanagavel D, Fedyanin M, Tryakin A, et al. Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol, 2015, 21(41): 11621-11635.
18.	Guan E, Tian F, Liu Z. A novel risk score model for stomach adenocarcinoma based on the expression levels of 10 genes. Oncol Lett, 2020, 19(2): 1351-1367.
19.	周紅, 郭春光, 陳應泰, 等. 早期胃癌非治愈性內鏡黏膜下剝離術后的治療策略研究. 中華腫瘤雜志, 2019, 41(11): 865-869.
20.	Xu W, Beeharry MK, Liu W, et al. Preoperative chemotherapy for gastric cancer: personal interventions and precision medicine. Biomed Res Int, 2016, 2016: 3923585.
21.	Seevaratnam R, Bocicariu A, Cardoso R, et al. How many lymph nodes should be assessed in patients with gastric cancer? A systematic review. Gastric Cancer, 2012, 15 Suppl 1: S70-S88.
22.	魏晟宏, 陳路川, 葉再生, 等. 胃癌腫瘤大小的臨床病理特征及預后分析(附 753 例報告). 福建醫藥雜志, 2017, 39(6): 88-91.
23.	Deng JY, Liang H. Clinical significance of lymph node metastasis in gastric cancer. World J Gastroenterol, 2014, 20(14): 3967-3975.
24.	Min CL, Zhang AX, Qin J. Increased expression of miR-601 is associated with poor prognosis and tumor progression of gastric cancer. Diagn Pathol, 2019, 14(1): 107.
25.	周薇薇, 雷海科, 李小升, 等. 2 187 例胃癌患者生存隨訪調查及預后影響因素研究. 消化腫瘤雜志(電子版), 2020, 12(2): 105-111.
26.	Zheng Z, Liu Y, Bu Z, et al. Prognostic role of lymph node metastasis in early gastric cancer. Chin J Cancer Res, 2014, 26(2): 192-199.
27.	Yamada S, Hatta W, Shimosegawa T, et al. Different risk factors between early and late cancer recurrences in patients without additional surgery after noncurative endoscopic submucosal dissection for early gastric cancer. Gastrointest Endosc, 2019, 89(5): 950-960.
28.	Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376(9742): 687-697.
29.	Yang Y, Yin X, Sheng L, et al. Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated meta-analysis. Sci Rep, 2015, 5: 12850.

1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol, 2017, 3(4): 524-548.
2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
3. Eusebi LH, Telese A, Marasco G, et al. Gastric cancer prevention strategies: A global perspective. J Gastroenterol Hepatol, 2020, 35(9): 1495-1502.
4. Machlowska J, Baj J, Sitarz M, et al. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci, 2020, 21(11): 4012.
5. Habib R, Akhtar J, Taqi M, et al. Lentiviral vector-mediated survivin shRNA delivery in gastric cancer cell lines significantly inhibits cell proliferation and tumor growth. Oncol Rep, 2015, 34(2): 859-867.
6. 徐冉, 楊年釗, 趙海遠, 等. 多灶性胃癌病人淋巴結轉移危險因素及預后分析. 臨床外科雜志, 2020, 28(8): 774-777.
7. 許巧玲, 鄭鴻. 伊立替康聯合阿帕替尼治療晚期胃癌預后分析. 腫瘤研究與臨床, 2020, 32(6): 419-423.
8. Zhao Z, Fan Y, Sun Y, et al. Efficacy of conversion surgery on stage Ⅳ gastric cancer and its prognosis analysis. Panminerva Med, 2020 May 14. Online ahead of print.
9. 崔勇, 張榮香, 王福立, 等. 新輔助化療聯合術后同步放化療治療Ⅲ期胃癌的療效分析. 中國腫瘤臨床, 2016, 43(17): 747-752.
10. 李敏娜, 路寧, 王藝璇, 等. 中青年與老年胃癌術后患者的臨床病理特點和預后因素—基于 SEER 數據庫的分析. 現代腫瘤醫學, 2020, 28(14): 2467-2473.
11. 李靜. miRNA-451 表達與胃癌患者預后相關性分析. 慢性病學雜志, 2020, 21(7): 974-976.
12. 馬翔. 胃癌手術治療后超長期生存患者預后因素分析. 腫瘤研究與臨床, 2019, 31(9): 630-632.
13. 蔣大平, 徐華平, 方華進, 等. 影響胃癌根治術后患者預后效果的相關因素分析. 中國現代醫學雜志, 2020, 30(4): 39-43.
14. 廖玉麟, 徐宏濤, 周煜. 營養狀況及心理因素對胃癌患者半年生存率及生存質量的影響. 中國現代醫生, 2016, 54(10): 30-33.
15. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin, 2017, 67(2): 93-99.
16. Liu JY, Peng CW, Yang XJ, et al. The prognosis role of AJCC/UICC 8 th edition staging system in gastric cancer, a retrospective analysis. Am J Transl Res, 2018, 10(1): 292-303.
17. Kanagavel D, Fedyanin M, Tryakin A, et al. Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol, 2015, 21(41): 11621-11635.
18. Guan E, Tian F, Liu Z. A novel risk score model for stomach adenocarcinoma based on the expression levels of 10 genes. Oncol Lett, 2020, 19(2): 1351-1367.
19. 周紅, 郭春光, 陳應泰, 等. 早期胃癌非治愈性內鏡黏膜下剝離術后的治療策略研究. 中華腫瘤雜志, 2019, 41(11): 865-869.
20. Xu W, Beeharry MK, Liu W, et al. Preoperative chemotherapy for gastric cancer: personal interventions and precision medicine. Biomed Res Int, 2016, 2016: 3923585.
21. Seevaratnam R, Bocicariu A, Cardoso R, et al. How many lymph nodes should be assessed in patients with gastric cancer? A systematic review. Gastric Cancer, 2012, 15 Suppl 1: S70-S88.
22. 魏晟宏, 陳路川, 葉再生, 等. 胃癌腫瘤大小的臨床病理特征及預后分析(附 753 例報告). 福建醫藥雜志, 2017, 39(6): 88-91.
23. Deng JY, Liang H. Clinical significance of lymph node metastasis in gastric cancer. World J Gastroenterol, 2014, 20(14): 3967-3975.
24. Min CL, Zhang AX, Qin J. Increased expression of miR-601 is associated with poor prognosis and tumor progression of gastric cancer. Diagn Pathol, 2019, 14(1): 107.
25. 周薇薇, 雷海科, 李小升, 等. 2 187 例胃癌患者生存隨訪調查及預后影響因素研究. 消化腫瘤雜志(電子版), 2020, 12(2): 105-111.
26. Zheng Z, Liu Y, Bu Z, et al. Prognostic role of lymph node metastasis in early gastric cancer. Chin J Cancer Res, 2014, 26(2): 192-199.
27. Yamada S, Hatta W, Shimosegawa T, et al. Different risk factors between early and late cancer recurrences in patients without additional surgery after noncurative endoscopic submucosal dissection for early gastric cancer. Gastrointest Endosc, 2019, 89(5): 950-960.
28. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376(9742): 687-697.
29. Yang Y, Yin X, Sheng L, et al. Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated meta-analysis. Sci Rep, 2015, 5: 12850.

Previous Article
Risk factors for hypoparathyroidism following radical resection of thyroid papillary carcinoma
Next Article
Risk factors of lymph node metastasis in papillary thyroid microcarcinoma with cN0

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Influencing factors of postoperative survival in patient with gastric cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content